Abstract
The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in carcinogenesis in gastrointestinal (GI) cancers including esophagus, gastric and colorectal cancers has triggered the researches of COX-2 inhibitors as the chemopreventive option for GI cancers. This reviewer updates the current molecular biology on the regulation of COX-2 expression, pharmacological concepts of COX-2 inhibitors in the chemoprevention of GI tract, the clinical efficacies of COX -2 inhibitors in prevention of cancers in GI tract and associated main adverse events. In inflammation, COX-2 expression is regulated both at the transcriptional and posttranscriptional levels. Hypermethylation of the CpG island in the COX-2 gene is the major cause of COX-2 silencing in a subset of GI cancers. However, the tumor-inhibitory efficacy of non-selective non-steroidal antiinflammatory drugs (NSAIDs) or selective COX-2 inhibitors is not necessarily related to their COX-inhibitory potential. These compounds harbor additional pharmacological activities that are entirely independent of its COX-2 inhibitory activity. The clearly identified targets relevant for anticancer therapy, the benefits from clinical chemoprevention of GI tract cancers and the absence of adverse findings of cardiovascular function or histopathology in preclinical toxicology studies indicate the promising results of COX-2 inhibitors. The efficacy and toxicity of NSAIDs are a consequence of the inhibition of the COX enzymes. Therefore, an optimal regime of COX-2 inhibitors in chemoprevention of GI cancers should be further investigated probably by adjustment of dosage, duration, integration of co-therapy and careful selection of candidates.
Keywords: Cyclooxygenase 2, esophagus cancer, gastric cancer, colorectal cancer, Cyclooxygenase 2 inhibitor, aspirin, celecoxib, rofecoxib, carcinogenesis, dosage
Current Pharmaceutical Design
Title:Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors
Volume: 19 Issue: 1
Author(s): Rui Wang, Linjie Guo, Pu Wang, Wenjuan Yang, Yaoyao Lu, Zhiyin Huang and Chengwei Tang
Affiliation:
Keywords: Cyclooxygenase 2, esophagus cancer, gastric cancer, colorectal cancer, Cyclooxygenase 2 inhibitor, aspirin, celecoxib, rofecoxib, carcinogenesis, dosage
Abstract: The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in carcinogenesis in gastrointestinal (GI) cancers including esophagus, gastric and colorectal cancers has triggered the researches of COX-2 inhibitors as the chemopreventive option for GI cancers. This reviewer updates the current molecular biology on the regulation of COX-2 expression, pharmacological concepts of COX-2 inhibitors in the chemoprevention of GI tract, the clinical efficacies of COX -2 inhibitors in prevention of cancers in GI tract and associated main adverse events. In inflammation, COX-2 expression is regulated both at the transcriptional and posttranscriptional levels. Hypermethylation of the CpG island in the COX-2 gene is the major cause of COX-2 silencing in a subset of GI cancers. However, the tumor-inhibitory efficacy of non-selective non-steroidal antiinflammatory drugs (NSAIDs) or selective COX-2 inhibitors is not necessarily related to their COX-inhibitory potential. These compounds harbor additional pharmacological activities that are entirely independent of its COX-2 inhibitory activity. The clearly identified targets relevant for anticancer therapy, the benefits from clinical chemoprevention of GI tract cancers and the absence of adverse findings of cardiovascular function or histopathology in preclinical toxicology studies indicate the promising results of COX-2 inhibitors. The efficacy and toxicity of NSAIDs are a consequence of the inhibition of the COX enzymes. Therefore, an optimal regime of COX-2 inhibitors in chemoprevention of GI cancers should be further investigated probably by adjustment of dosage, duration, integration of co-therapy and careful selection of candidates.
Export Options
About this article
Cite this article as:
Wang Rui, Guo Linjie, Wang Pu, Yang Wenjuan, Lu Yaoyao, Huang Zhiyin and Tang Chengwei, Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors, Current Pharmaceutical Design 2013; 19 (1) . https://dx.doi.org/10.2174/1381612811306010115
DOI https://dx.doi.org/10.2174/1381612811306010115 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association between Serum Vitamin D Level and Echocardiographic Abnormalities in Patients with Thalassemia Major
Cardiovascular & Hematological Disorders-Drug Targets The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Essential Polymers Helping Patients with Obesity
Current Applied Polymer Science Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Hydrogen Sulfide as a New Endogenous Gaseous Transmitter in the Cardiovascular System
Current Vascular Pharmacology Genomics-Based Identification of Molecular Mechanisms behind the Cancer Preventive Action of Phytochemicals: Potential and Challenges
Current Pharmaceutical Biotechnology Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Meeting Report The Third Annual PepTalk Meeting: The Human Proteome
Current Proteomics Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Multi-Target QSAR Approaches for Modeling Protein Inhibitors. Simultaneous Prediction of Activities Against Biomacromolecules Present in Gram-Negative Bacteria
Current Topics in Medicinal Chemistry Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Highly Efficient, Chemoselective Syntheses of 2-Methoxy-4-substituted Pyrimidines
Letters in Organic Chemistry Probiotics and the Intestinal Microflora: What Impact on the Immune System, Infections and Aging?
Current Nutrition & Food Science Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders